# Amivantamab trial in advanced head‑neck cancer

> Live situation record from CLSTR: https://clstr.news/situations/enfortumab-vedotin-combos-in-bladder-cancer
> Updated: 2026-06-03T08:27:26.000Z. Sources: 151. Developments: 6.

In late May 2026, a multinational Phase II study of Johnson & Johnson’s sub‑cutaneous antibody amivantamab was presented at the ASCO meeting in Chicago. The trial enrolled 102 patients with advanced head‑and‑neck cancers across 11 countries. Results showed tumor shrinkage in 43 participants and complete disappearance in 15, yielding an overall response rate of about one‑third. Median overall survival was reported at 12.5 months and progression‑free interval around 6‑6.5 months, with most adverse events mild to moderate and fewer than 10 % discontinuing therapy.

Subsequent reports over the next days reiterated these findings, added details on median survival, highlighted comments from Professor Kevin Harrington, and quoted a patient experience. The data prompted the launch of larger Phase III studies (OrigAMI‑4, OrigAMI‑5) aiming to enroll up to 500 patients, with sites expanding to the United States, United Kingdom, Vietnam, Greece, Portugal and other regions. The drug, already approved for non‑small‑cell lung cancer, is also being investigated in around 60 trials for additional solid tumours such as lung, colorectal, brain and stomach cancers.

## Timeline

### 2026-06-03: Amivantamab cancer drug trial starts at five Portuguese hospitals

Johnson & Johnson’s amivantamab, a subcutaneous drug that blocks EGFR and MET, showed complete tumor disappearance in 15 of 102 head‑and‑neck cancer patients at ASCO, and a Phase III trial will enroll 500 pts,

2 sources. https://clstr.news/cluster/amivantamab-cancer-drug-trial-starts-at-five-portuguese-hospitals

### 2026-06-02: Amivantamab therapy achieves complete tumor disappearance in advanced cancer trial

Amivantamab, a Johnson & Johnson antibody, caused tumor shrinkage in 43 of 102 advanced cancer patients, with 15 complete responses, in an 11‑country trial.

2 sources. https://clstr.news/cluster/amivantamab-therapy-achieves-complete-tumor-disappearance-in-advanced-cancer-trial

### 2026-06-01: Amivantamab injection eliminates tumors in late‑stage head‑neck cancer trial

Amivantamab, a Johnson & Johnson subcutaneous injection, shrank or eliminated tumors in 43 of 102 late‑stage head‑neck cancer patients, with 15 complete responses, in an international trial presented at ASCO.

3 sources. https://clstr.news/cluster/amivantamab-injection-eliminates-tumors-in-latestage-headneck-cancer-trial

### 2026-05-31: Amivantamab injection shrinks tumors in resistant head‑neck cancer patients

Amivantamab injection, by Johnson & Johnson, led to tumor shrinkage or disappearance in 42% of resistant head‑neck cancer patients in a multi‑country trial, showing promising survival outcomes.

2 sources. https://clstr.news/cluster/amivantamab-injection-shrinks-tumors-in-resistant-headneck-cancer-patients

### 2026-05-31: Amivantamab injection eradicates tumors in late‑stage head‑neck cancer

Amivantamab, a triple‑action injection from Johnson & Johnson, eradicated tumors in 15 of 102 late‑stage head‑neck cancer patients, with mild side effects and a median survival of 12.5 months.

2 sources. https://clstr.news/cluster/amivantamab-injection-eradicates-tumors-in-latestage-headneck-cancer

### 2026-05-29: Johnson & Johnson's amivantamab trial shows tumor elimination in some patients

Amivantamab, a Johnson & Johnson injection, cut tumors in over a third of head‑and‑neck cancer patients and erased them completely in 15 cases in an 11‑country trial.

140 sources. https://clstr.news/cluster/enfortumab-vedotinpembrolizumab-combo-shows-longterm-survival-gain-in-firstline-urothelial-cancer

---
Cite as: Amivantamab trial in advanced head‑neck cancer. CLSTR, https://clstr.news/situations/enfortumab-vedotin-combos-in-bladder-cancer